ALGORAND-FOUNDATION
The Algorand Foundation today announced the appointment of Dr. Tal Rabin as the head of research. Named on Forbes World Top 50 Women in Tech 2018 and a member of the National Academy of Arts and Sciences, Dr. Tal Rabin has spent decades pioneering research on cryptographic theory. Dr. Rabin will bring her wealth of experience, specifically around multiparty computations and the design of efficient and provably secure cryptographic protocols, to her work at the foundation.
With core beliefs in the establishment of an open, public and permissionless blockchain, the Algorand Foundation has a vision for an inclusive ecosystem that provides an opportunity for everyone to harness the potential of an equitable and truly borderless economy. With the appointment of Dr. Tal Rabin as the head of research, the foundation is poised to make that vision a reality with broad participation and a focus on cutting-edge research and innovation.
A first-of-its-kind permissionless, pure proof-of-stake blockchain, the Algorand protocol was designed by MIT professor, cryptography pioneer and Turing Award-winner Silvio Micali to support the scale, open participation, and transaction finality needed by users to build opportunity and fulfill the promise of blockchain technology. The Algorand Foundation directs its global efforts from Singapore and is focused on building technology and community around decentralized networks. The foundation, along with the Algorand community, will help launch the Algorand blockchain network while also assisting with research efforts, collaborative roadmap development, and continued growth of the global community.
“Given Dr. Rabin’s experience and academic accomplishments, the Algorand Foundation will be able to take a leadership role in research related to fair access, social justice for all, as well as zero knowledge and secure computation,” said Silvio Micali, founder of Algorand, Inc. “Tal brings tremendous energy to these issues, and I have always admired her passion for philanthropic efforts enabled by technology and innovation, particularly when it comes to her unwavering commitment to gender equality. I am thrilled she has agreed to join the Algorand community.”
“I’ve always believed in the concept of making our world a fairer place, and I trust the Algorand blockchain can create the economic opportunity needed to make that world a reality,” said Rabin. “Our work at the Algorand Foundation will ensure that equitable access to opportunity through decentralized technologies exists, transactions flow freely and everyone has control over their data. I’m excited to start working toward that goal with the accomplished team at the Algorand Foundation.”
In the coming weeks, the Algorand Foundation will share more details about the public network, including the distribution of Algos – the official native token of the Algorand protocol – as well as information about grants for research and development, growth, and economic guidance.
About Algorand Foundation
The Algorand Foundation is providing the trusted infrastructure needed to support the growth of the borderless economy. With research led by Dr. Tal Rabin, a 2018 Forbes World Top 50 Women in Tech, the Algorand Foundation is incorporated in the Republic of Singapore.
For more information, visit https://algorand.foundation .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190502005123/en/
Contact:
Kalyn Schieffer March Communications algorandfoundation@marchcomms.com 617-960-9948
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased16.7.2025 09:15:00 CEST | Press release
Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life. Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health. The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein. This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily i
The Future of Connectivity Starts Here: Network X Returns to Paris October 14 - 1616.7.2025 09:00:00 CEST | Press release
Show Reconvenes at Paris Expo Porte de Versailles with Global Representation of Industry Leaders and Telco Experts Network X 2025 - the only event that brings the fixed and mobile markets together - returns to Paris Expo Porte de Versailles October 14 - 16. Built for telecom's top players, this annual show drives business model innovation and monetisation of next-generation fixed, mobile, satellite and transport networks through AI and cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716595903/en/ Speaker on Headliners Stage at Network X 2024 New to Network X in 2025 are specialty events designed to deliver expert insights on trending topics including Data Center World and two Expo Stages for Fixed-Line and Mobile. More than 5,500 telco network infrastructure professionals will gather alongside 1,500 telcos to learn from six program tracks highlighting the latest advancements in Fibre, Wi-Fi Networks and Services, IP
Skechers AERO Series Opens New Chapter of Technical Running Innovation16.7.2025 09:00:00 CEST | Press release
New Collection Features an Evolution in Design that Cuts Through the Wind for That Aerodynamic Feel on Every Run Skechers Performance opens a new chapter of running innovation with the arrival of the Skechers AERO series. Named for the aerodynamic feel of the design, Skechers AERO represents the latest evolution of technical running shoes from the brand. The collection is engineered to deliver an exhilarating blend of speed, style and comfort to help runners cut through the wind and push beyond their personal bests while logging miles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716754749/en/ Introducing the Skechers AERO Series of technical running shoes: Skechers AERO Burst, Skechers AERO Spark, and Skechers AERO Tempo (L-R). “Recently launched in North America and Asia, the AERO Series leverages innovative technologies to elevate our signature comfort that’s now available to runners in Europe,” said Ben Stewart, Vic
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom